{"transactions":[{"id":702272,"issuer":{"id":5494,"kind":"organization","name":"Scribe Therapeutics, Inc."},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-07-29T01:30:16.000Z","date":"2026-07-28","kind":"purchase","planned":false,"acquired":true,"shares":7905,"price":18.25,"value":144266.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (\"Avoro Capital Advisors\") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (\"Avoro Ventures\") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2)."}],"balance_after":3088888,"source":{"system":"sec-edgar","filing":"0000902664-26-003270","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000090266426003270/ownership.xml","form_type":"4"}},{"id":702271,"issuer":{"id":5494,"kind":"organization","name":"Scribe Therapeutics, Inc."},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-07-29T01:30:16.000Z","date":"2026-07-24","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":22.31,"value":1115500.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (\"Avoro Capital Advisors\") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (\"Avoro Ventures\") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2)."}],"balance_after":3080983,"source":{"system":"sec-edgar","filing":"0000902664-26-003270","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000090266426003270/ownership.xml","form_type":"4"}},{"id":702270,"issuer":{"id":5494,"kind":"organization","name":"Scribe Therapeutics, Inc."},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-07-29T01:30:16.000Z","date":"2026-07-24","kind":"purchase","planned":false,"acquired":true,"shares":2333333,"price":15,"value":34999995.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the \"IPO\") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC (\"Avoro Life Sciences\") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. (\"Avoro Ventures Fund\" and, together with Avoro Life Sciences, the \"Funds\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (\"Avoro Capital Advisors\") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (\"Avoro Ventures\") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2)."}],"balance_after":3030983,"source":{"system":"sec-edgar","filing":"0000902664-26-003270","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000090266426003270/ownership.xml","form_type":"4"}},{"id":703039,"issuer":{"id":5494,"kind":"organization","name":"Scribe Therapeutics, Inc."},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-28T01:04:25.000Z","date":"2026-07-23","kind":"grant","planned":false,"acquired":true,"shares":14725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's (\"Dr. Aghazadeh\") provision of service to the Issuer on each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company (\"Avoro Capital Advisors\"), and Avoro Ventures LLC, a Delaware limited liability company (\"Avoro Ventures,\" together with Dr. Aghazadeh and Avoro Capital Advisors, the \"Reporting Persons\"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":14725,"derivative":{"exercise_price":15,"expiration_date":"2036-07-22","underlying":"Common Stock","underlying_shares":14725},"source":{"system":"sec-edgar","filing":"0000902664-26-003254","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000090266426003254/ownership.xml","form_type":"4"}},{"id":737985,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-15T21:18:58.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":38040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. \"Date of Grant\" shall mean June 12, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (\"Avoro Capital Advisors\"), Avoro Ventures LLC, a Delaware limited liability company (\"Avoro Ventures\") and Behzad Aghazadeh (\"Dr. Aghazadeh\", and together with Avoro Capital Advisors and Avoro Ventures, the \"Reporting Persons\"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":38040,"derivative":{"exercise_price":4.16,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":38040},"source":{"system":"sec-edgar","filing":"0001701815-26-000006","document":"form4-06152026_090652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000170181526000006/form4-06152026_090652.xml","form_type":"4"}},{"id":779396,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":1,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":2,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Pre-funded Warrant (right to buy)","published_at":"2026-05-14T23:40:47.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":6377714,"price":3.9199,"value":25000001.1086,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors (as defined below) directly from the Issuer in a private placement."},{"field":"shares","element":"transactionShares","label":"F1","text":"The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors (as defined below) directly from the Issuer in a private placement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after May 12, 2026, exercise the Pre-funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the Reporting Persons cannot exercise any of the Pre-Funded Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 19.99% of the outstanding Common Stock (the \"19.99% Blocker\"). Consequently, at this time, the Reporting Persons are not able to exercise all the Pre-Funded Warrants due to the 19.99% Blocker."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after May 12, 2026, exercise the Pre-funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the Reporting Persons cannot exercise any of the Pre-Funded Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 19.99% of the outstanding Common Stock (the \"19.99% Blocker\"). Consequently, at this time, the Reporting Persons are not able to exercise all the Pre-Funded Warrants due to the 19.99% Blocker."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (\"Avoro Capital Advisors\"), Avoro Ventures LLC, a Delaware limited liability company (\"Avoro Ventures\") and Behzad Aghazadeh (\"Dr. Aghazadeh\", and together with Avoro Capital Advisors and Avoro Ventures, the \"Reporting Persons\"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":14710714,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":6377714},"source":{"system":"sec-edgar","filing":"0000902664-26-002449","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000090266426002449/ownership.xml","form_type":"4"}},{"id":1109976,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-16T20:51:43.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":40006,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. \"Date of Grant\" shall mean June 12, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (\"Avoro Capital Advisors\"), Avoro Ventures LLC, a Delaware limited liability company (\"Avoro Ventures\") and Behzad Aghazadeh (\"Dr. Aghazadeh\", and together with Avoro Capital Advisors and Avoro Ventures, the \"Reporting Persons\"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":40006,"derivative":{"exercise_price":2.04,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":40006},"source":{"system":"sec-edgar","filing":"0001415889-25-017406","document":"form4-06162025_080637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000141588925017406/form4-06162025_080637.xml","form_type":"4"}},{"id":1229504,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Pre-funded Warrant (right to buy)","published_at":"2025-03-04T22:56:37.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":8333000,"price":2.3999,"value":19998366.7,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors and Avoro Ventures (as defined below) directly from the Issuer in a private placement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after March 4, 2025, exercise the Pre-funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the Reporting Persons cannot exercise any of the Pre-Funded Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 19.99% of the outstanding Common Stock (the \"19.99% Blocker\"). Consequently, at this time, the Reporting Persons are not able to exercise all the Pre-Funded Warrants due to the 19.99% Blocker."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after March 4, 2025, exercise the Pre-funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the Reporting Persons cannot exercise any of the Pre-Funded Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 19.99% of the outstanding Common Stock (the \"19.99% Blocker\"). Consequently, at this time, the Reporting Persons are not able to exercise all the Pre-Funded Warrants due to the 19.99% Blocker."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (\"Avoro Capital Advisors\"), Avoro Ventures LLC, a Delaware limited liability company (\"Avoro Ventures\") and Behzad Aghazadeh (\"Dr. Aghazadeh\", and together with Avoro Capital Advisors and Avoro Ventures, the \"Reporting Persons\"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":8333000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":8333000},"source":{"system":"sec-edgar","filing":"0000902664-25-001334","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000090266425001334/ownership.xml","form_type":"4"}},{"id":1479367,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:12:40.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":45832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. \"Date of Grant\" shall mean June 12, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (\"Avoro Capital Advisors\"), Avoro Ventures LLC, a Delaware limited liability company (\"Avoro Ventures\") and Behzad Aghazadeh (\"Dr. Aghazadeh\", and together with Avoro Capital Advisors and Avoro Ventures, the \"Reporting Persons\"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":45832,"derivative":{"exercise_price":1.7,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":45832},"source":{"system":"sec-edgar","filing":"0001415889-24-016874","document":"form4-06142024_080636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000141588924016874/form4-06142024_080636.xml","form_type":"4"}},{"id":1849972,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T00:59:11.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":28255,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant.  \"Date of Grant\" shall mean June 15, 2023."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (\"Avoro Capital Advisors\"), Avoro Ventures LLC, a Delaware limited liability company (\"Avoro Ventures\") and Behzad Aghazadeh (\"Dr. Aghazadeh\", and together with Avoro Capital Advisors and Avoro Ventures, the \"Reporting Persons\"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":28255,"derivative":{"exercise_price":8.2,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":28255},"source":{"system":"sec-edgar","filing":"0001209191-23-038675","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000120919123038675/doc4.xml","form_type":"4"}},{"id":2151338,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2022-09-26T21:46:06.000Z","date":"2022-09-22","kind":"grant","acquired":true,"shares":1260000,"price":12.5,"value":15750000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors and Avoro Ventures (as defined below) directly from the Issuer in a private placement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (\"Avoro Capital Advisors\"), Avoro Ventures LLC, a Delaware limited liability company (\"Avoro Ventures\") and Behzad Aghazadeh (\"Dr. Aghazadeh\", and together with Avoro Capital Advisors and Avoro Ventures, the \"Reporting Persons\"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":3471752,"source":{"system":"sec-edgar","filing":"0000902664-22-004356","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000090266422004356/ownership.xml","form_type":"4"}},{"id":2228301,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T20:21:45.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18573,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant.  \"Date of Grant\" shall mean June 15, 2022."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (\"Avoro Capital Advisors\"), Avoro Ventures LLC, a Delaware limited liability company (\"Avoro Ventures\") and Behzad Aghazadeh (\"Dr. Aghazadeh\", and together with Avoro Capital Advisors and Avoro Ventures, the \"Reporting Persons\"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":18573,"derivative":{"exercise_price":13.46,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":18573},"source":{"system":"sec-edgar","filing":"0001209191-22-037859","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000120919122037859/doc4.xml","form_type":"4"}},{"id":2586797,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Stock option (right to buy)","published_at":"2021-08-30T23:39:23.000Z","date":"2021-08-27","kind":"grant","acquired":true,"shares":17549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the closing of the Merger, as approved by the stockholders of the Issuer on August 17, 2021, the Board granted on August 26, 2021 to the Reporting Person an Initial Award (as defined in the Issuer's Outside Director Compensation Policy and in accordance with the Issuer's 2021 Equity Incentive Plan (the \"Plan\")). Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month). The grant date is August 27, 2021."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (\"Avoro Capital Advisors\"), Avoro Ventures LLC, a Delaware limited liability company (\"Avoro Ventures\") and Behzad Aghazadeh (\"Dr. Aghazadeh\", and together with Avoro Capital Advisors and Avoro Ventures, the \"Reporting Persons\"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"In connection with the closing of the Merger, as approved by the stockholders of the Issuer on August 17, 2021, the Board granted on August 26, 2021 to the Reporting Person an Initial Award (as defined in the Issuer's Outside Director Compensation Policy and in accordance with the Issuer's 2021 Equity Incentive Plan (the \"Plan\")). Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month). The grant date is August 27, 2021."}],"balance_after":17549,"derivative":{"exercise_price":26,"expiration_date":"2031-08-27","underlying":"Common Stock","underlying_shares":17549},"source":{"system":"sec-edgar","filing":"0000902664-21-004071","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000090266421004071/ownership.xml","form_type":"4"}},{"id":2586796,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":28272,"kind":"person","name":"Aghazadeh Behzad","position":1,"cik":"0001701815","reported_name":"Aghazadeh Behzad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":28273,"kind":"person","name":"Avoro Capital Advisors LLC","position":2,"cik":"0001633313","reported_name":"Avoro Capital Advisors LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":28274,"kind":"person","name":"Avoro Ventures LLC","position":3,"cik":"0001879253","reported_name":"Avoro Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2021-08-30T23:39:23.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":1911752,"price":13.077,"value":24999980.904,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (\"Avoro Capital Advisors\"), Avoro Ventures LLC, a Delaware limited liability company (\"Avoro Ventures\") and Behzad Aghazadeh (\"Dr. Aghazadeh\", and together with Avoro Capital Advisors and Avoro Ventures, the \"Reporting Persons\"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors and Avoro Ventures directly from the Issuer in a PIPE financing completed in connection with the closing of the Agreement and Plan of Merger between the Issuer and Aadi Bioscience, Inc., dated as of May 16, 2021, following which the Issuer changed its name to Aadi Bioscience, Inc."}],"balance_after":2211752,"source":{"system":"sec-edgar","filing":"0000902664-21-004071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879253/000090266421004071/ownership.xml","form_type":"4"}}]}